KAM
RIGL icon

Kazazian Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Kazazian Asset Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$24K Hold
1,277
– – 0.03% 56
2019
Q2 		$33K Sell
1,277
-167
-12% -$3.77K 0.04% 64
2019
Q1 		$37K Buy
+1,444
New +$33K 0.05% 59

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Kazazian Asset Management's RIGL Position: Q3 2019 in Review

Kazazian Asset Management held its Rigel Pharmaceuticals (RIGL) position steady in Q3 2019 at 1,277 shares worth $24K. The position accounts for 0.03% of the portfolio, ranked #56.

Kazazian Asset Management first reported a position in RIGL in Q1 2019 and has held it in 3 quarters since. The position peaked at $37K in Q1 2019. 131 funds tracked by Wall St. Rank hold RIGL as of Q3 2019.

  • Kazazian Asset Management held 1,277 shares of Rigel Pharmaceuticals worth $24K as of Q3 2019.
  • Kazazian Asset Management left its Rigel Pharmaceuticals share count unchanged in Q3 2019.
  • Rigel Pharmaceuticals made up 0.03% of Kazazian Asset Management's portfolio in Q3 2019, its #56 holding.
  • Kazazian Asset Management first reported a position in Rigel Pharmaceuticals in Q1 2019 and has held it in 3 quarters since.
  • Kazazian Asset Management's Rigel Pharmaceuticals position peaked at $37K in Q1 2019.
  • 131 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2019.

Based on Kazazian Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.